{"id":954633,"date":"2026-04-24T15:43:05","date_gmt":"2026-04-24T19:43:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaros-anticipatory-breach-claim\/"},"modified":"2026-04-24T15:43:05","modified_gmt":"2026-04-24T19:43:05","slug":"delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaros-anticipatory-breach-claim","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaros-anticipatory-breach-claim\/","title":{"rendered":"Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro\u2019s Anticipatory Breach Claim"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"margin-bottom:6pt\">Ruling preserves current contracted royalty rates and rejects Tesaro\u2019s request for any royalty reduction<\/li>\n<li style=\"margin-bottom:6pt\">Trial to adjudicate Anaptys\u2019 contract claims and right to seek reversion of <em>Jemperli<\/em> against Tesaro\/GSK is scheduled for July 14-17, 2026\n<\/li>\n<\/ul>\n<p align=\"left\">SAN DIEGO, April  24, 2026  (GLOBE NEWSWIRE) &#8212; AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for <em>Jemperli<\/em> with GSK and imsidolimab with Vanda, today announced that the Delaware Chancery Court has dismissed Tesaro\u2019s anticipatory breach of contract claim against Anaptys. The ruling agrees with Anaptys\u2019 position that it has never repudiated the Collaboration and Exclusive License Agreement (\u201cCollaboration Agreement\u201d) with Tesaro, a subsidiary of GSK, governing the development and commercialization of <em>Jemperli<\/em>.<\/p>\n<p>As stated in Anaptys\u2019 original filing, the company\u2019s motion explained \u201cwhy, as a matter of law, Anaptys has never repudiated the Collaboration Agreement and how Anaptys has only sought to vindicate its contract rights.\u201d The Court\u2019s decision confirms that Tesaro\u2019s anticipatory breach of contract claim was insufficiently pleaded and rejects Tesaro\u2019s request for any royalty reduction.<\/p>\n<p>\u201cThe Court\u2019s decision affirms what we have maintained from the beginning: Tesaro\u2019s anticipatory breach claim was baseless, and this ruling is an important validation of our efforts to protect our contractual rights to the <em>Jemperli<\/em> royalty stream for our shareholders,\u201d said Dan Faga, president and chief executive officer of Anaptys. \u201cWe are enforcing Tesaro\/GSK\u2019s contractual duty to seek <em>Jemperli<\/em>\u2019s optimal commercial return, as well as enforcing our other contractual rights that Tesaro\/GSK have materially violated, including by pursuing our right for reversion of <em>Jemperli<\/em>. We continue to prepare for trial scheduled for July and remain confident we will prevail in our litigation against Tesaro\/GSK.\u201d<\/p>\n<p>As previously disclosed, Anaptys approached\u00a0Tesaro\u00a0to engage in good faith discussions to potentially resolve Anaptys\u2019 claims that\u00a0Tesaro\u00a0and GSK had breached the Collaboration Agreement. On\u00a0Nov. 20, 2025,\u00a0Tesaro, without notice to Anaptys and with discussions ongoing, initiated a lawsuit against Anaptys, seeking a declaration that\u00a0Tesaro\u00a0had not breached and claiming that Anaptys had repudiated the Collaboration Agreement.<\/p>\n<p>In response, Anaptys filed its own Complaint in\u00a0Delaware Chancery Court, requesting a court declaration that\u00a0Tesaro\u00a0has materially breached the parties\u2019 Collaboration Agreement and that GSK, Tesaro\u2019s corporate parent, has tortiously interfered with the Collaboration Agreement.<\/p>\n<p>Anaptys\u2019 Complaint centers on claims that Tesaro has breached multiple core provisions in the Collaboration Agreement and if Tesaro is found to be in breach of even one of these provisions, Anaptys is entitled to <em>Jemperli<\/em>\u2019s reversion to Anaptys under the Collaboration Agreement. Among other things, Anaptys claims that:<\/p>\n<ul type=\"disc\">\n<li>Tesaro has materially breached the Collaboration Agreement\u2019s exclusivity duty by engaging in development activities with competitive therapeutics, and Tesaro\u2019s reading of the provision strips it of meaning to purportedly allow Tesaro (and GSK) to engage in any development work with competitors so long as dostarlimab has some minimal involvement;<\/li>\n<li>Tesaro has breached the Collaboration Agreement\u2019s diligence duty, which requires Tesaro to seek <em>Jemperli<\/em>\u2019s \u201c<em>optimum <\/em>commercial return,\u201d a high bar that Tesaro agreed but failed, to meet; and<\/li>\n<li>Tesaro has materially breached the Collaboration Agreement\u2019s notice duties due to Tesaro\u2019s failure to notify Anaptys regarding its clinical trial plans, including where those plans involved testing with competitive therapeutics.\n<\/li>\n<\/ul>\n<p>The trial is scheduled for July 14-17, 2026.<\/p>\n<p>\n        <strong>About Anaptys\u2019 Collaboration and Exclusive License Agreement with Tesaro (an affiliate of GSK)<\/strong>\n      <\/p>\n<p>In March 2014, Anaptys entered into the Collaboration Agreement with Tesaro, an oncology-focused biopharmaceutical company now a part of GSK. Currently, under the Collaboration Agreement, Tesaro is developing <em>Jemperli<\/em> (dostarlimab) as a monotherapy, and in combination with additional therapies, for various solid tumor indications.<\/p>\n<p>Anaptys is eligible to receive royalties upon sales of <em>Jemperli<\/em>, equal to 8% of net sales below $1.0 billion, 12% of net sales between $1.0 billion and $1.5 billion, 20% of net sales between $1.5 billion and $2.5 billion and 25% of net sales above $2.5 billion.<\/p>\n<p>The royalty term under this collaboration extends at least through expiration of composition of matter coverage on the molecule, which expires in 2035 in the\u00a0U.S., in 2036 in the EU and in 2037 in Japan, with the potential for patent-term extensions into 2038.<\/p>\n<p>\n        <strong>About Anaptys<\/strong>\n      <\/p>\n<p>Anaptys manages the financial collaborations for <em>Jemperli<\/em> with GSK and imsidolimab with Vanda, with a focus on protecting and returning the value of its royalties to shareholders. To learn more, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=81oB7bxDA_vpJZYpj6cRhdJYBFMcYGX0WaQGC8p5QsXH8-jXwsGq7-btJPDpQ1J7TBq1MH_T_OeXuPHx9eLtO8HylT-6llOyACo2-0lud5c=\" rel=\"nofollow\" target=\"_blank\">www.AnaptysBio.com<\/a> or follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uYTC3jbhHb8dyvAI-jOFw_kYiKy8_NPZ_aZipoXkekaNuiEzZ4lHC0gTIuaKVBo9N_fQytSH_EoL29SR2_spWshbt0lW3eEiWI3Imbcx-48=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>This press release contains forward-looking statements within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the timing and potential outcome of proceedings in Delaware Chancery Court between Anaptys, Tesaro, and GSK, the nature of the remedies either party may seek or obtain in such proceedings, and the timing or amount of royalties from the sales of <em>Jemperli<\/em>. Statements including words such as \u201cplan,\u201d \u201ccontinue,\u201d \u201cexpect,\u201d or \u201congoing\u201d and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company\u2019s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company\u2019s ability to advance its product candidates, obtain regulatory approval of and ultimately commercialize its product candidates, the timing and results of preclinical and clinical trials, the company\u2019s ability to fund development activities and achieve development goals, the company\u2019s ability to protect intellectual property and other risks and uncertainties described under the heading \u201cRisk Factors\u201d in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.<\/p>\n<p>\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Anaptys Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aDjtplWH0k1vHVOxIyqkoH7K5lJrm32ncnx5m_d7u_kHpo3m-kNH8DbgOjqeExi5tdKxQ5I54wGtF-lnvTiEE2n7GFQyMD-1Ue0cTL-bVcLtGher1K4DqJgHGRAVyeLj\" rel=\"nofollow\" target=\"_blank\">investors@anaptysbio.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5Njc5NiM3NTU1MTQ0IzIwMjAxMjY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/Nzc5OTYxNjEtYzhhNC00YTc1LTlhOGEtNzM2MGVjNjE0ZTRiLTEwMzE2OTgtMjAyNi0wNC0yNC1lbg==\/tiny\/AnaptysBio-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ruling preserves current contracted royalty rates and rejects Tesaro\u2019s request for any royalty reduction Trial to adjudicate Anaptys\u2019 contract claims and right to seek reversion of Jemperli against Tesaro\/GSK is scheduled for July 14-17, 2026 SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) &#8212; AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that the Delaware Chancery Court has dismissed Tesaro\u2019s anticipatory breach of contract claim against Anaptys. The ruling agrees with Anaptys\u2019 position that it has never repudiated the Collaboration and Exclusive License Agreement (\u201cCollaboration Agreement\u201d) with Tesaro, a subsidiary of GSK, governing the development and commercialization of Jemperli. As stated in Anaptys\u2019 original filing, the company\u2019s &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaros-anticipatory-breach-claim\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro\u2019s Anticipatory Breach Claim&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-954633","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro\u2019s Anticipatory Breach Claim - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaros-anticipatory-breach-claim\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro\u2019s Anticipatory Breach Claim - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Ruling preserves current contracted royalty rates and rejects Tesaro\u2019s request for any royalty reduction Trial to adjudicate Anaptys\u2019 contract claims and right to seek reversion of Jemperli against Tesaro\/GSK is scheduled for July 14-17, 2026 SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) &#8212; AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that the Delaware Chancery Court has dismissed Tesaro\u2019s anticipatory breach of contract claim against Anaptys. The ruling agrees with Anaptys\u2019 position that it has never repudiated the Collaboration and Exclusive License Agreement (\u201cCollaboration Agreement\u201d) with Tesaro, a subsidiary of GSK, governing the development and commercialization of Jemperli. As stated in Anaptys\u2019 original filing, the company\u2019s &hellip; Continue reading &quot;Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro\u2019s Anticipatory Breach Claim&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaros-anticipatory-breach-claim\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-24T19:43:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5Njc5NiM3NTU1MTQ0IzIwMjAxMjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaros-anticipatory-breach-claim\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaros-anticipatory-breach-claim\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro\u2019s Anticipatory Breach Claim\",\"datePublished\":\"2026-04-24T19:43:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaros-anticipatory-breach-claim\\\/\"},\"wordCount\":1017,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaros-anticipatory-breach-claim\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5Njc5NiM3NTU1MTQ0IzIwMjAxMjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaros-anticipatory-breach-claim\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaros-anticipatory-breach-claim\\\/\",\"name\":\"Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro\u2019s Anticipatory Breach Claim - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaros-anticipatory-breach-claim\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaros-anticipatory-breach-claim\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5Njc5NiM3NTU1MTQ0IzIwMjAxMjY=\",\"datePublished\":\"2026-04-24T19:43:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaros-anticipatory-breach-claim\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaros-anticipatory-breach-claim\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaros-anticipatory-breach-claim\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5Njc5NiM3NTU1MTQ0IzIwMjAxMjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5Njc5NiM3NTU1MTQ0IzIwMjAxMjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaros-anticipatory-breach-claim\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro\u2019s Anticipatory Breach Claim\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro\u2019s Anticipatory Breach Claim - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaros-anticipatory-breach-claim\/","og_locale":"en_US","og_type":"article","og_title":"Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro\u2019s Anticipatory Breach Claim - Market Newsdesk","og_description":"Ruling preserves current contracted royalty rates and rejects Tesaro\u2019s request for any royalty reduction Trial to adjudicate Anaptys\u2019 contract claims and right to seek reversion of Jemperli against Tesaro\/GSK is scheduled for July 14-17, 2026 SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) &#8212; AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that the Delaware Chancery Court has dismissed Tesaro\u2019s anticipatory breach of contract claim against Anaptys. The ruling agrees with Anaptys\u2019 position that it has never repudiated the Collaboration and Exclusive License Agreement (\u201cCollaboration Agreement\u201d) with Tesaro, a subsidiary of GSK, governing the development and commercialization of Jemperli. As stated in Anaptys\u2019 original filing, the company\u2019s &hellip; Continue reading \"Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro\u2019s Anticipatory Breach Claim\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaros-anticipatory-breach-claim\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-24T19:43:05+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5Njc5NiM3NTU1MTQ0IzIwMjAxMjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaros-anticipatory-breach-claim\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaros-anticipatory-breach-claim\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro\u2019s Anticipatory Breach Claim","datePublished":"2026-04-24T19:43:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaros-anticipatory-breach-claim\/"},"wordCount":1017,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaros-anticipatory-breach-claim\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5Njc5NiM3NTU1MTQ0IzIwMjAxMjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaros-anticipatory-breach-claim\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaros-anticipatory-breach-claim\/","name":"Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro\u2019s Anticipatory Breach Claim - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaros-anticipatory-breach-claim\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaros-anticipatory-breach-claim\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5Njc5NiM3NTU1MTQ0IzIwMjAxMjY=","datePublished":"2026-04-24T19:43:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaros-anticipatory-breach-claim\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaros-anticipatory-breach-claim\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaros-anticipatory-breach-claim\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5Njc5NiM3NTU1MTQ0IzIwMjAxMjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5Njc5NiM3NTU1MTQ0IzIwMjAxMjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaros-anticipatory-breach-claim\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro\u2019s Anticipatory Breach Claim"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/954633","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=954633"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/954633\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=954633"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=954633"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=954633"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}